Illumina, Inc. $ILMN Shares Purchased by Ethic Inc.

Ethic Inc. increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 23.1% in the second quarter, Holdings Channel reports. The firm owned 16,678 shares of the life sciences company’s stock after acquiring an additional 3,125 shares during the period. Ethic Inc.’s holdings in Illumina were worth $1,581,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Diversified Trust Co acquired a new stake in Illumina in the first quarter valued at approximately $355,000. Bourgeon Capital Management LLC grew its position in Illumina by 76.4% in the second quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock valued at $13,538,000 after acquiring an additional 61,468 shares in the last quarter. GC Wealth Management RIA LLC acquired a new stake in Illumina in the second quarter valued at approximately $2,289,000. waypoint wealth counsel acquired a new stake in Illumina in the second quarter valued at approximately $321,000. Finally, Allegiance Financial Group Advisory Services LLC bought a new position in Illumina during the second quarter worth $344,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 0.1%

NASDAQ:ILMN opened at $100.11 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The firm has a market capitalization of $15.39 billion, a price-to-earnings ratio of 12.67, a price-to-earnings-growth ratio of 2.47 and a beta of 1.40. The stock has a fifty day simple moving average of $98.17 and a 200 day simple moving average of $91.65.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the company posted $0.36 EPS. Illumina’s revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ILMN shares. Robert W. Baird set a $105.00 price objective on Illumina in a research note on Friday. Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Daiwa Capital Markets cut Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th. Citigroup cut Illumina from a “hold” rating to a “strong sell” rating and cut their target price for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Royal Bank Of Canada set a $124.00 target price on Illumina in a report on Tuesday, September 2nd. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.